Volanesorsen: Ph III COMPASS data

The 26-week, double-blind, international Phase III COMPASS trial in 113 patients with severe hypertriglyceridemia showed that once-weekly 300 mg subcutaneous volanesorsen

Read the full 216 word article

User Sign In